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Background
Down-scaling, parallelization and automation are new
trends in the field of recombinant protein expression in
the post genomic era [1-3]. During the past years many
companies and academic institutions have heavily
invested in process and automation technologies. Does
this trend keep its promise? Can post genomic protein
production issues be overcome with few automated proc-
esses?
This abstract wants to highlight two years of experience in
running a Protein Production Center in an industrial envi-
ronment applying the expression systems BEVS, E. coli
(and transient HEK.EBNA). We describe the streamlined
and partially automated processes, the automation equip-
ment applied; discuss results from the past two years of
experience and strategies to eliminate remaining bottle-
necks.
Results
Proteins expressed in a generic way in the E. coli expres-
sion system are all his-tagged and often N-terminally
fused to thioredoxin or other fusion partners in order to
improve solubility. After small scale expression evaluation
in 24-deepwell blocks recombinant proteins are produced
in 1-L fermenter vessels using fully automated and unat-
tended inductions and temperature shifts. The described
method is applicable to all host strains and induction sys-
tems, providing the optimal induction time point and
harvest for each construct.
To run the BEVS in an automated high throughput envi-
ronment still represents a major challenge. In order to
meet this challenge, we have developed robust automated
protocols at various formats for the small scale BEV proc-
ess on an epMOTION 5070 workstation and semi auto-
mated large scale protocols for 10-L wave bioreactors and
purification on Akta 3D and Akta Express. The expression
of DUB family and various other proteins were used as an
example to validate these processes (Table 1).
During the validation of the technologies described above
some weak points of the automated processes became
obvious: the tendency of proteins to form soluble or
insoluble aggregates at any stage of the process and the
presence of proteases, which requires close control of the
fermentation process and interferes with fully automated
and unattended runs. While means to control the aggrega-
tion phenomenon are still under investigation, a generic
method has been found to control the proteolysis issue in
the BEVS. We demonstrate that the addition of 10 mM of
the cysteine protease inhibitor E-64 during the course of
production effectively reduces/prevents proteolytic degra-
dation of various recombinant proteins over a minimum
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Microbial Cell Factories 2006, 5(Suppl 1):P60of 72 hours of culture time, thus improving the quality
and yields of secreted as well as intracellular recombinant
proteins (Figure 1).
Conclusion
We have demonstrated that recombinant protein expres-
sion can be evaluated, scaled up and proteins be purified
in a parallel and (semi-) automated fashion using the
BEVS and E. coli expression systems. Pre-requisites are that
proteins are appropriately tagged and grouped. However,
in order to attain optimal quality and yield of different
recombinant proteins by generic processes the influence
of protein destabilizing factors needs to be thoroughly
understood and managed.
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Effect of the addition of E-64 (cysteine protease inhibitor) and Pepstatin A (aspartic acid protease inhibitor) on the expression o  a secret d wn  a tagonist in Sf21 infected insect cells.Figure 1
Effect of the addition of E-64 (cysteine protease inhibitor) and Pepstatin A (aspartic acid protease inhibitor) on the expression 
of a secreted wnt antagonist in Sf21 infected insect cells.(A): Western Blot (α-His) of cell lysates and medium supernatants 
taken at various time points (48, 67, 73, 90, 97 hours) post infection (expected size of protein: 28.1 kDa).
+ pepstatin A (5μM)
Total cell lysate Supernatant Total cell lysate Supernatant Total cell lysate
     
Supernatant
+ E-64 (10μM)without inhibitor 
M      48 67 73 90 97 48 67 73 90  97h     M   48 67 73 90  97 48 67 73 90  97h    M  48 67 73 90  97     48 67 73 90  97h 
Table 1: Expression of 30 DUB proteins in the BEVS at 10-L scale and processed in a semi-automated mode.
Analysis Method AVERAGE RANGE Av. Yield [%]
Small Scale Expression [mg/L] ELISA 27 3 – 140
Large Scale Expression [mg/l] ELISA 43 0 – 270
Large Scale Expression [mg] ELISA 448 0 – 1400 100 %
Cross-flow yields [mg] ELISA 169 0 – 825 41 %
Pure protein yields [mg] HPLC 21 0 – 103 (16%)*
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